$TGTX (TG Therapeutics, Inc.) — investor discussion on X

Five-factor rating: Strong Buy (sector percentile 89.5%)

Graded daily on value B-, growth B+, profitability A, momentum B+, revisions A-. Sector-relative, identical for every user.

Most active credible voices on $TGTX

@semodough (dough) — 132 mentions · 44.5K followers
@equitydd (Equity investor) — 28 mentions · 11.3K followers
@dennisc230 (Dennis C) — 11 mentions · 28.5K followers

Recent headlines featuring $TGTX

2026-10-27: Bitcoin short-term holder profit share cools to about 70%, Glassnode data shows

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $TGTX are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

For richer charts and full features, open SpikePanel on desktop.

$TGTX — what investors on X are saying · SpikePanel

$TGTXTG Therapeutics, Inc. · Biotechnology · $8.6B

$56.77

+0.6%

Event thread

Key events, in time order

6 items

2026-08-05CapitalBull
Empowered Funds Lifts TGTX Stake by 49.9%
Institutional 13F filing shows significant stake increase, reflecting fund positioning
D1 +2.3% · +5d -0.8%
2026-08-03Earnings
TGTX Q2 Revenue Beat, EPS Miss, FY Guidance Raised
Q2 revenue $240M beat, EPS $0.05 miss, but BRIUMVI strength raises FY guidance to $950M
D1 -11.3% · +5d +6.5%
2 waves of this story
- 2026-08-03 Q2 total revenue ~$240M, BRIUMVI US net revenue $228M (+64% YoY), FY target raised to ~$950M, but EPS $0.05 vs $0.41 est.
- 2026-08-03 Q2 revenue $240M beat, EPS $0.05 miss, but BRIUMVI strength raises FY guidance to $950M

4 earlier events

2026-08-03Earnings
Earnings report
D1 -11.3% · +5d +6.5%
2026-08-038-K filing
8-K: Item 2.02, Item 9.01
D1 -11.3% · +5d +6.5%
2026-07-29 → 08-01Earnings
TG Therapeutics to Report Q2 Earnings Before Open on Aug 3
Multiple sources confirm earnings timing, market awaits results
D1 -2.5% · +5d -6.7%
2 waves of this story
- 2026-07-29 Company to report Q2 results and business update Monday morning, latest official schedule.
- 2026-08-01 Multiple sources confirm earnings timing, market awaits results
2026-07-28OtherBull
TGTX on IBD Top 15 and Short-Squeeze Lists
Multiple independent X accounts list TGTX in IBD Top 15 and short-pain lists, indicating heightened attention
D1 -1.6% · +5d -11.2%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

6 items

2026-08-05CapitalBull
Empowered Funds Lifts TGTX Stake by 49.9%
Institutional 13F filing shows significant stake increase, reflecting fund positioning
D1 +2.3% · +5d -0.8%
2026-08-03Earnings
TGTX Q2 Revenue Beat, EPS Miss, FY Guidance Raised
Q2 revenue $240M beat, EPS $0.05 miss, but BRIUMVI strength raises FY guidance to $950M
D1 -11.3% · +5d +6.5%
2 waves of this story
- 2026-08-03 Q2 total revenue ~$240M, BRIUMVI US net revenue $228M (+64% YoY), FY target raised to ~$950M, but EPS $0.05 vs $0.41 est.
- 2026-08-03 Q2 revenue $240M beat, EPS $0.05 miss, but BRIUMVI strength raises FY guidance to $950M
2026-08-03Earnings
Earnings report
D1 -11.3% · +5d +6.5%
2026-08-038-K filing
8-K: Item 2.02, Item 9.01
D1 -11.3% · +5d +6.5%
2026-07-29 → 08-01Earnings
TG Therapeutics to Report Q2 Earnings Before Open on Aug 3
Multiple sources confirm earnings timing, market awaits results
D1 -2.5% · +5d -6.7%
2 waves of this story
- 2026-07-29 Company to report Q2 results and business update Monday morning, latest official schedule.
- 2026-08-01 Multiple sources confirm earnings timing, market awaits results

1 earlier events

2026-07-28OtherBull
TGTX on IBD Top 15 and Short-Squeeze Lists
Multiple independent X accounts list TGTX in IBD Top 15 and short-pain lists, indicating heightened attention
D1 -1.6% · +5d -11.2%

$TGTX (TG Therapeutics, Inc.) — investor discussion on X

Five-factor rating: Strong Buy (sector percentile 89.5%)

Most active credible voices on $TGTX

Recent headlines featuring $TGTX

$TGTX (TG Therapeutics, Inc.) — investor discussion on X

Five-factor rating: Strong Buy (sector percentile 89.5%)

Most active credible voices on $TGTX

Recent headlines featuring $TGTX

Empowered Funds Lifts TGTX Stake by 49.9%

TGTX Q2 Revenue Beat, EPS Miss, FY Guidance Raised

Earnings report

8-K: Item 2.02, Item 9.01

TG Therapeutics to Report Q2 Earnings Before Open on Aug 3

TGTX on IBD Top 15 and Short-Squeeze Lists

Bull vs bear

Discussion

Empowered Funds Lifts TGTX Stake by 49.9%

TGTX Q2 Revenue Beat, EPS Miss, FY Guidance Raised

Earnings report

8-K: Item 2.02, Item 9.01

TG Therapeutics to Report Q2 Earnings Before Open on Aug 3

TGTX on IBD Top 15 and Short-Squeeze Lists